| Anuka Das, MD | |
|
1 Boston Medical Ctr Pl Ste 1, Boston, MA 02118-2999 | |
| (617) 414-4465 | |
| (617) 414-3345 |
| Full Name | Anuka Das |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 5 Years |
| Location | 1 Boston Medical Ctr Pl Ste 1, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285194480 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 1014299 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Boston Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dothouse Health Inc. | 8729991021 | 39 |
News Archive
Universitätsmedizin Berlin in collaboration with the Sanger Institute in Cambridge and other cooperation partners in Belgium, the Netherlands and France, were able to identify a genetic defect that is responsible for the development of TAR Syndrome, a congenital malformation of the skeleton and blood.
MMI-USA, a subsidiary of Memometal Technologies S.A., France, a global leader in the manufacture and development of extremity orthopedics, announced today the expansion of its U.S. and worldwide patent and trademark programs. Memometal recognizes the value of its intellectual property and is committed to protecting its products through aggressive procurement and enforcement of patent and trademark rights.
Among the changes included in the president's 2014 budget blueprint are the elimination of the SGR formula to set Medicare physician payment rates, and funding boosts for mental health and food and drug safety. The proposal also delays funding cuts to hospitals that treat the uninsured.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.
› Verified 3 days ago
| Entity Name | Dothouse Health Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578514733 PECOS PAC ID: 8729991021 Enrollment ID: O20031112000264 |
News Archive
Universitätsmedizin Berlin in collaboration with the Sanger Institute in Cambridge and other cooperation partners in Belgium, the Netherlands and France, were able to identify a genetic defect that is responsible for the development of TAR Syndrome, a congenital malformation of the skeleton and blood.
MMI-USA, a subsidiary of Memometal Technologies S.A., France, a global leader in the manufacture and development of extremity orthopedics, announced today the expansion of its U.S. and worldwide patent and trademark programs. Memometal recognizes the value of its intellectual property and is committed to protecting its products through aggressive procurement and enforcement of patent and trademark rights.
Among the changes included in the president's 2014 budget blueprint are the elimination of the SGR formula to set Medicare physician payment rates, and funding boosts for mental health and food and drug safety. The proposal also delays funding cuts to hospitals that treat the uninsured.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.
› Verified 3 days ago
| Entity Name | Boston University Family Medicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134166390 PECOS PAC ID: 0446154074 Enrollment ID: O20031125000010 |
News Archive
Universitätsmedizin Berlin in collaboration with the Sanger Institute in Cambridge and other cooperation partners in Belgium, the Netherlands and France, were able to identify a genetic defect that is responsible for the development of TAR Syndrome, a congenital malformation of the skeleton and blood.
MMI-USA, a subsidiary of Memometal Technologies S.A., France, a global leader in the manufacture and development of extremity orthopedics, announced today the expansion of its U.S. and worldwide patent and trademark programs. Memometal recognizes the value of its intellectual property and is committed to protecting its products through aggressive procurement and enforcement of patent and trademark rights.
Among the changes included in the president's 2014 budget blueprint are the elimination of the SGR formula to set Medicare physician payment rates, and funding boosts for mental health and food and drug safety. The proposal also delays funding cuts to hospitals that treat the uninsured.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.
› Verified 3 days ago
| Entity Name | Boston University Obstetrics And Gynecology Foundation Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063459568 PECOS PAC ID: 1456323153 Enrollment ID: O20070525000149 |
News Archive
Universitätsmedizin Berlin in collaboration with the Sanger Institute in Cambridge and other cooperation partners in Belgium, the Netherlands and France, were able to identify a genetic defect that is responsible for the development of TAR Syndrome, a congenital malformation of the skeleton and blood.
MMI-USA, a subsidiary of Memometal Technologies S.A., France, a global leader in the manufacture and development of extremity orthopedics, announced today the expansion of its U.S. and worldwide patent and trademark programs. Memometal recognizes the value of its intellectual property and is committed to protecting its products through aggressive procurement and enforcement of patent and trademark rights.
Among the changes included in the president's 2014 budget blueprint are the elimination of the SGR formula to set Medicare physician payment rates, and funding boosts for mental health and food and drug safety. The proposal also delays funding cuts to hospitals that treat the uninsured.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anuka Das, MD 1 Bmc Place, Boston, MA 02118 Ph: (617) 414-4465 | Anuka Das, MD 1 Boston Medical Ctr Pl Ste 1, Boston, MA 02118-2999 Ph: (617) 414-4465 |
News Archive
Universitätsmedizin Berlin in collaboration with the Sanger Institute in Cambridge and other cooperation partners in Belgium, the Netherlands and France, were able to identify a genetic defect that is responsible for the development of TAR Syndrome, a congenital malformation of the skeleton and blood.
MMI-USA, a subsidiary of Memometal Technologies S.A., France, a global leader in the manufacture and development of extremity orthopedics, announced today the expansion of its U.S. and worldwide patent and trademark programs. Memometal recognizes the value of its intellectual property and is committed to protecting its products through aggressive procurement and enforcement of patent and trademark rights.
Among the changes included in the president's 2014 budget blueprint are the elimination of the SGR formula to set Medicare physician payment rates, and funding boosts for mental health and food and drug safety. The proposal also delays funding cuts to hospitals that treat the uninsured.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.
› Verified 3 days ago
Lidya H Wlasiuk, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 850 Harrison Ave, Yacc 5, Boston, MA 02118 Phone: 617-414-2080 Fax: 617-414-2090 | |
Brian R Penti, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 850 Harrison Ave, Yacc 4, Boston, MA 02118 Phone: 617-414-2080 Fax: 617-414-2090 | |
Alysia L Green, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 915 Commonwealth Ave Rear, Boston, MA 02215 Phone: 617-358-3400 Fax: 617-358-3710 | |
Shahnaz Rahman, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 Harrison Ave, Boston, MA 02118 Phone: 404-259-4008 | |
Dr. Amy Min He, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 637 Washington St, Boston, MA 02124 Phone: 617-825-9660 | |
Katherine A Gergen Barnett, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Melnea Cass Blvd, Boston, MA 02119 Phone: 617-414-2080 Fax: 617-414-2090 | |
Dr. Xiangxin Chen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 145 South St, Boston, MA 02111 Phone: 617-482-7555 Fax: 617-482-2930 |